Expression, purification, and characterization of active recombinant prostate-specific antigen in Pichia pastoris (yeast).

Autor: Habeck LL; Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. lhabeck@lilly.com, Belagaje RM, Becker GW, Hale JE, Churgay LM, Ulmer M, Yang XY, Shackelford KA, Richardson JM, Johnson MG, Mendelsohn LG
Jazyk: angličtina
Zdroj: The Prostate [Prostate] 2001 Mar 01; Vol. 46 (4), pp. 298-306.
DOI: 10.1002/1097-0045(20010301)46:4<298::aid-pros1036>3.0.co;2-j
Abstrakt: Background: Prostate-specific antigen (PSA), a member of the kallikrein family of serine proteases, is a chymotrypsin-like glycoprotein produced by the prostate epithelium. Elevated serum PSA (> 4 ng/ml) is a tumor marker for prostatic cancer and benign prostatic hypertrophy; increasing serum PSA over time is indicative of metastatic disease. It has been suggested that PSA may contribute to tumor metastasis through degradation of extracellular matrix glycoproteins, as well as cleavage of IGF binding protein-3, a modulator of IGF-1. To elucidate the role of PSA in the development and progression of prostatic cancer, it is necessary to have a reliable, cost-effective source of enzymatically active protein. Previous efforts to express recombinant PSA (rPSA) produced inactive proPSA, or mixtures of active and inactive PSA requiring activation by removal of the propeptide. We describe the expression of active recombinant mature PSA in yeast.
Methods: Stable chromosomal integration of a construct consisting of the yeast alpha-factor signal sequence preceding the mature PSA sequence resulted in secretion of rPSA. The rPSA was purified from the yeast cell culture supernatant to homogeneity by strong cation-exchange chromatography, and characterized by SDS-PAGE, Western analysis, electrospray mass spectrometry, N-glycanase digestion, N-terminal amino acid sequencing, and inactivation by a PSA-specific inhibitor.
Results: We report the production of active, mature rPSA in Pichia pastoris. Two forms of rPSA varying slightly in glycosylation were identified. The specific activity of the rPSA was equal to that of human seminal plasma PSA (0.56 micromol/min mg) as determined using a chromogenic substrate.
Conclusions: Large-scale production of active rPSA will be useful in the exploration of PSA effects on tumor cell proliferation, migration and metastasis. In addition, a large supply of enzyme should facilitate the discovery of novel inhibitors for in vitro and in vivo evaluation, and may provide a reproducible source of rPSA for use as a standard in diagnostic testing.
(Copyright 2001 Wiley-Liss, Inc.)
Databáze: MEDLINE
Externí odkaz: